PRZ-SILDENAFIL TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

SILDENAFIL (SILDENAFIL CITRATE)

Saadav alates:

PHARMARIS CANADA INC

ATC kood:

G04BE03

INN (Rahvusvaheline Nimetus):

SILDENAFIL

Annus:

100MG

Ravimvorm:

TABLET

Koostis:

SILDENAFIL (SILDENAFIL CITRATE) 100MG

Manustamisviis:

ORAL

Ühikuid pakis:

4/8

Retsepti tüüp:

Prescription

Terapeutiline ala:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0136261003; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2017-09-22

Toote omadused

PRODUCT MONOGRAPH
PR
PRZ-SILDENAFIL
Sildenafil (as Sildenafil citrate)
Tablets 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
Pharmaris Canada Inc.
Date of Revision:
8310-130
th
Street, Suite 102,
November 26, 2019
Surrey, British Columbia
V3W 8J9
Control # 233376
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................
4
ADVERSE REACTIONS
........................................................................................................................
7
DRUG INTERACTIONS
.......................................................................................................................
12
DOSAGE AND ADMINISTRATION
...................................................................................................
15
OVERDOSAGE
.....................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
.................................................................................
17
STORAGE AND STABILITY
..............................................................................................................
19
SPECIAL HANDLING INSTRUCTIONS
............................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................. 20
PART II: SCIENTIFIC INFORMAT